NCT00332761

Caduet in an Untreated Subject Population

An 8-Week Randomized, Double-Blind, Placebo-Controlled Trial Examining The Efficacy And Safety Of Caduet® In Simultaneously Achieving Blood Pressure And Lipid Goals In An Untreated Hypertensive And Dyslipidemic Subject Population. (CUSP - Caduet in Untreated Subject Population)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 220 (planned)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if Caduet will lower blood pressure to \<140/90 mmHg and lower LDL Cholesterol to \<100 mg/dL in subjects with hypertension and dyslipidemia who are not currently being treated for these medical conditions.

Conditions

• Hypertension
• Dyslipidemia

Interventions

Type	Name	Description
DRUG	Caduet

Timeline

• Start date: 2006-06-01
• Completion: 2007-09-01
• First posted: 2006-06-02
• Last updated: 2021-01-27

Locations

34 sites across 1 country: United States